Literature DB >> 18486954

Newborn screening for sickle cell disease in a Nigerian hospital.

M E Odunvbun1, A A Okolo, C M Rahimy.   

Abstract

UNLABELLED: Sickle cell disease (SCD) is the most common genetic disorder to affect Blacks. The mortality rate associated with SCD has remained high despite the use of appropriate interventions to manage the various forms of crisis. In developed countries, newborn screening programmes are conducted routinely, which has resulted in a reduction in the SCD mortality rate from 16% to <1%. In developing countries where the disease is prevalent, newborn screening programmes are yet to be established, and the acceptability of such programmes by the parents of newly delivered infants is unknown.
OBJECTIVES: This study was carried out to determine the acceptability of newborn screening for SCD on mothers of newly delivered infants, and to establish disease prevalence amongst a newborn population in Nigeria. STUDY
DESIGN: This prospective cross-sectional study was conducted at St. Philomena's Hospital, Benin City with mothers of newly delivered infants and their newborn babies.
METHODS: Newly delivered mothers were recruited consecutively into the study. Knowledge of their own haemoglobin phenotype status was assessed, and their wishes regarding SCD screening of their babies were determined. Babies were screened using isofocusing electrophoresis.
RESULTS: Six hundred and thirty mothers, delivered of 649 babies, were recruited into this study. Nineteen sets of babies were twins. Two mothers refused screening for their babies and 628 mothers or caregivers accepted screening; hence the acceptance rate was 99.7%. Four hundred and fifty-seven (71%) mothers did not know their own haemoglobin phenotype. Six hundred and forty-seven babies were screened for SCD. Of these, two samples were lost to testing and one baby had an indeterminate result; these three cases were not included in the analysis. Of the 644 babies whose results were analysed, 332 (51.6%) were male, 312 (48.4%) were female, 485 (75.3%) were AA, 133 (20.6%) were AS, seven (1.1%) were AC, 18 (2.8%) were SS, and one (0.2%) was SC.
CONCLUSION: The majority of mothers in this study did not know their haemoglobin phenotype. Newborn screening for SCD was acceptable to 99.7% of the mothers. The prevalence of SCD in the newborn population was 3% (2.8% SS and 0.2% SC).

Entities:  

Mesh:

Year:  2008        PMID: 18486954     DOI: 10.1016/j.puhe.2008.01.008

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   2.427


  24 in total

1.  A Cost-Effectiveness Analysis of a Pilot Neonatal Screening Program for Sickle Cell Anemia in the Republic of Angola.

Authors:  Patrick T McGann; Scott D Grosse; Brigida Santos; Vysolela de Oliveira; Luis Bernardino; Nicholas J Kassebaum; Russell E Ware; Gladstone E Airewele
Journal:  J Pediatr       Date:  2015-10-23       Impact factor: 4.406

Review 2.  The pressing need for point-of-care diagnostics for sickle cell disease: A review of current and future technologies.

Authors:  Patrick T McGann; Carolyn Hoppe
Journal:  Blood Cells Mol Dis       Date:  2017-08-08       Impact factor: 3.039

3.  Newborn screening for sickle cell disease: an innovative pilot program to improve child survival in Dar es Salaam, Tanzania.

Authors:  Siana Nkya; Lillian Mtei; Deogratias Soka; Vera Mdai; Promise B Mwakale; Paul Mrosso; Issa Mchoropa; Stella Rwezaula; Mary Azayo; Nzovu Ulenga; Melkiory Ngido; Sharon E Cox; Brenda S D'Mello; Honorati Masanja; Gregory S Kabadi; Frederick Mbuya; Bruno Mmbando; Yvonne Daniel; Allison Streetly; Japhet Killewo; Furahini Tluway; Magdalena Lyimo; Julie Makani
Journal:  Int Health       Date:  2019-11-13       Impact factor: 2.473

4.  A comparison of iron and folate with folate alone in hematologic recovery of children treated for acute malaria.

Authors:  Samuel N Gara; Aboi J K Madaki; Tom D Thacher
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

5.  Prevalence of Sickle Cell Trait and Reliability of Self-Reported Status among Expectant Parents in Nigeria: Implications for Targeted Newborn Screening.

Authors:  Amanda R Burnham-Marusich; Chinenye O Ezeanolue; Michael C Obiefune; Wei Yang; Alice Osuji; Amaka G Ogidi; Aaron T Hunt; Dina Patel; Echezona E Ezeanolue
Journal:  Public Health Genomics       Date:  2016-09-10       Impact factor: 2.000

6.  High birth prevalence of sickle cell disease in Northwestern Tanzania.

Authors:  Emmanuela E Ambrose; Julie Makani; Neema Chami; Tulla Masoza; Rogatus Kabyemera; Robert N Peck; Erasmus Kamugisha; Alphaxard Manjurano; Neema Kayange; Luke R Smart
Journal:  Pediatr Blood Cancer       Date:  2017-08-02       Impact factor: 3.167

7.  Hydroxyurea therapy in adult Nigerian sickle cell disease: a monocentric survey on pattern of use, clinical effects and patient's compliance.

Authors:  Ademola Samson Adewoyin; Omokiniovo Sunday Oghuvwu; Omolade Augustina Awodu
Journal:  Afr Health Sci       Date:  2017-03       Impact factor: 0.927

8.  Empowering newborn screening programs in African countries through establishment of an international collaborative effort.

Authors:  Bradford L Therrell; Michele A Lloyd-Puryear; Kwaku Ohene-Frempong; Russell E Ware; Carmencita D Padilla; Emmanuela E Ambrose; Amina Barkat; Hassan Ghazal; Charles Kiyaga; Tisungane Mvalo; Obiageli Nnodu; Karim Ouldim; Mohamed Chérif Rahimy; Brígida Santos; Léon Tshilolo; Careema Yusuf; Guisou Zarbalian; Michael S Watson
Journal:  J Community Genet       Date:  2020-05-15

9.  Influence of gender norms in relation to child's quality of care: follow-up of families of children with SCD identified through NBS in Tanzania.

Authors:  Julie Makani; Michael Parker; Daima Bukini; Columba Mbekenga; Siana Nkya; Leonard Malasa; Sheryl McCurdy; Karim Manji
Journal:  J Community Genet       Date:  2020-08-12

10.  How to reach rapid diagnosis in sickle cell disease?

Authors:  Ehsan Valavi; Mohammad Javad Alemzadeh Ansari; Khodamorad Zandian
Journal:  Iran J Pediatr       Date:  2010-03       Impact factor: 0.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.